ST2 in Pulmonary Disease

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2015 English Publisher:Elsevier BVJournal:The American Journal of Cardiology, volume 115, pages 44B-47B (issn: 0002-9149,

Copyright policy )

Authors: Ednan K, Bajwa; Alexandre, Mebazaa; James L, Januzzi;

doi: 10.1016/j.amjcard.2015.01.040

pmid: 25665765

ST2 in Pulmonary Disease

- Summary
- Subjects
- Metrics

Abstract

In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of the ST2 pathway in clinical disease, including evidence that sST2 could be a useful biomarker in both allergic and nonallergic pulmonary disease.

Related Organizations

Massachusetts General Hospital
United States
University of Paris
France
Harvard University
United States
University of Paris
France

Keywords

Lung Diseases, Humans, Receptors, Cell Surface, Interleukin-1 Receptor-Like 1 Protein, Biomarkers

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	23
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average